Vilazodone Hydrochloride Tablet, Film Coated
Product Images NDC 69097-982

This is a description of Vilazodone Hydrochloride Tablets, a prescription-only medication. Each tablet contains 10mg of vilazodone hydrochloride and the usual dosage should be followed as per the package insert. The medication guide must be provided separately to each patient by the pharmacist. The tablets come in a sealed container and should be stored at 20° to 25°C (68° to 77°F). The medication is manufactured by InvaGen Pharmaceuticals, Inc. and marketed in the USA by Cipla USA, Inc.*

This is a medication called Vilazodone Hydrochloride, made by InvaGen Pharmaceuticals, that comes in a container with 30 tablets. Each tablet contains 20 mg of vilazodone hydrochloride. It should be stored at a temperature between 20°C to 25°C. This medication requires a prescription and pharmacists are instructed to dispense the medication guide to each patient. The package insert should be consulted for dosage information. This medication should be kept out of reach of children. Manufacturing took place in Hauppauge, NY 11788 while it is being distributed by Cipla USA, Inc. in Warren, NJ 07059.*

This is a description of a medication called Vilazodone Hydrochloride in the form of tablets. The tablets are dispensed with a medication guide for the patient and contain 40 mg of vilazodone hydrachloride. The manufacturer of this medication is Cipla and it is manufactured by InvaGen Pharmacsticals, Inc. for Cipla USA, Inc. The tablets must be kept in a tightly closed container and stored at a temperature between 20 to 25°C (68 to 77°F). The dosage instructions can be found inside the package insert. It is available in 30 tablet pack sizes and must be kept out of reach of children. The NDC number for this medication is 69097-982-02 and for prescription only.*

This appears to be a list of drugs and their effects on certain enzymes and protein levels within the body, with measurements of concentration and change in comparison to a reference. The text denotes possible changes due to ethanol, and drugs that inhibit or induce CYP3A4 enzymes, such as ketoconazole and carbamazepine respectively. Proton pump inhibitors, including pantoprazole, are also mentioned. The remaining text mentions measurements of PK, Cmax, and Auc, as well as "fold change" and "90% CI" with numbers for each. However, without additional information or formatting, it is difficult to determine what these numbers represent or what this information is being applied to.*

This text lists several substrates of different enzymes involved in drug metabolism, including CYP3A4, CYPIA2, CYP2D6, CYP2C9, CYP2C19, and P-gp. It also contains pharmacokinetic parameters, such as AUCp, CRmp, URmp, CLm, Um, Cmax, and AUC, as well as fold change and 90% confidence interval. However, the context or purpose of this information is not available.*